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ABSTRACT 
 
Melanoma is one of the most dangerous skin malignancies due to its high metastatic tendency and high 
mortality. Activation of key signaling pathways enforcing melanoma progression depends on 
phosphorylation of tyrosine kinases, and oxidative stress. We here investigated the effect of the new 
bis-coumarin derivative (3,5-DCPBC) on human melanoma cell survival, growth, proliferation, 
migration, and intracellular redox state, and deciphered associated signal pathways. This novel derivative 
was found to be toxic for melanoma cells, and non-toxic for their benign counterparts, melanocytes 
and fibroblasts. 3,5-DCPBC inhibited cell survival, migration and proliferation of different metastatic, and 
non-metastatic melanoma cell lines through the profound suppression of phosphorylation of the Epidermal 
Growth Factor receptor, and related downstream pathways. Suppression of phosphorylation of key 
downstream transcription factors and different tyrosine kinases comprise JAK/STAT, SRC kinases, ERK 
and MAP kinases (p38alpha), all involved in melanoma progression. Simultaneous and specific targeting 
of multiple tyrosine kinases and corresponding key genes in melanoma cells makes 3,5-DCPBC a highly 
interesting anti-melanoma, and anti-metastatic drug candidate which may in the long term hold promise in 
the therapy of advanced melanoma.  
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1. Introduction 
 
Malignant melanoma represents most aggressive and deadliest form of skin cancer (Stephanie et al., 
2020; Liu, Das, Liu, & Huang, 2018; Prado, Svoboda, & Rigel, 2019). Several systemic therapies 
(cytotoxic chemotherapy, targeted drugs, immunotherapy, hormonal therapy, radiation therapy, and bio-
chemotherapy) have been approved by the US Food and Drug Administration (FDA) (Domingues, Lopes, 
Soares, & Populo, 2018; Martin & Lo, 2018). Surgery still represents the first treatment option for primary 
melanoma when metastasis has not yet occurred. At later metastatic stages, systemic therapies are 
mandatory. The most successful treatment options against non-resettable metastatic melanoma are the 
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immunotherapy with antibodies directed against CTLA-4 and PD-1 (Ollila, Laks, & Hsueh, 2018) or their 
combination (de Golian, Kwong, Swetter, & Pugliese, 2016). The overall response rate of 10% to 15% for 
anti-CTLA-4 (ipilimumab), 25% to 45% for anti-PD-1 (nivolumab or pembrolizumab), and around 60% 
for their combination were embraced as a recent breakthrough in the therapy of this previously hard-to-
treat malignancy. However, due to the resistant nature of malignant melanoma (de Golian et al., 2016), 40% 
of the patients do not respond to the combined therapy (Lipson et al., 2018). In addition, severe, life-
threatening, or fatal side effects (50% only with anti-CTLA-4 immunotherapy, and even more with the 
combined anti-CTLA-4, and anti-PD-1 therapy), further fuels the urgent quest for new strategies in the 
battle against metastatic melanoma.  Several promising agents have been tested against single protein 
kinases in malignancies (Aittomaki & Pesu, 2014; de Golian et al., 2016; Eggermont & Robert, 2018; 
Miklossy, Hilliard, & Turkson, 2013). Phosphorylated-receptors of tyrosine/serine/threonine protein 
kinases and their downstream targets are molecular players enforcing cell growth, survival, 
proliferation and migration (Amaral et al., 2017; Cheng, Qi, Paudel, & Zhu, 2011; Day, Sosale, & Lazzara, 
2016; Xu & McArthur, 2016). A number of these effectors within distinct signaling pathways are 
hyperphosphorylated, and, in consequence,  hyperactivated in different cancers including melanoma 
(Maria Mendonça, Luís Soares de, & João Pedro, 2018). Some of the new therapeutic interventions against 
these kinases have successfully reached clinical trials, while others already have been approved by the 
US-FDA, and entered clinical routine (Kakadia et al., 2018). Currently, no single systemic therapy has 
been successful in the long term to prevent melanoma progression. Due to the emergence of resistance 
against these drugs, multiple phases II, and III melanoma trials are currently underway that are either 
studying the effect of combination treatments or striving for new synthetic, and natural compounds 
(Kourie & Klastersky, 2016; Kumar et al., 2017). Combined therapies targeting 2 tyrosine kinases at least 
delay the development of resistance (Hartmann et al., 2015; Popescu & Anghel, 2017). A newly emerging 
concept for the treatment of advanced malignant melanoma is based on uncovering new synthetic 
compounds targeting multiple signaling pathways and their corresponding genes. Bis-Coumarins, a  
benzophenone family of natural compounds, have previously been studied as potential drug candidates 
against various diseases including different types of cancers. They are, however, not endowed with the 
required potential to simultaneously target several signaling pathways (Salar et al., 2019). We here set out 
to evaluate the effect of a newly synthesized derivative of bis-coumarins, [3,3'-((3,5-dichlorophenyl) 
methylene)bis(4-hydroxychroman-2-one)] (3,5-DCPBC), on growth, survival, proliferation and migration 
of non-metastatic and metastatic melanoma cells, and to investigate its underlying molecular mode of 
action.  In the present study, we demonstrate that treatment of human metastatic, and non-metastatic 
melanoma cells with 3,5-DCPBC profoundly diminished phosphorylation of the Epidermal Growth 
Factor Receptor ( EGFR), and simultaneously suppressed phosphorylation of effectors in key 
downstream signaling pathways known to enforce melanoma progression. We also uncovered the non-
toxic nature of this compound against human melanocytes, the benign counterpart of malignant 
melanoma cells. In aggregate, we here report for the first time a novel anti-melanoma drug candidate that 
could not only suppress cellular functions, key for melanoma progression, but simultaneously target 
multiple phosphor-tyrosine kinases. This is a clinically relevant advancement, and thus, 3,5-DCPBC may 
hold unique therapeutic potential to be further tested in preclinical, and clinical studies. 
 
 
 
 
2. Materials and Methods 
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2.1. Cell lines, reagents, and antibodies 
Metastatic melanoma included A375 (#CRL-1619), SK-Mel-28 (#HTB-72), WM-266-4 (#CRL-1676) 
melanoma cell lines; non-metastatic melanoma comprised  the WM115 (#CRL-1675) melanoma cell line. 
These melanoma cell lines were procured from A.T.C.C, and normal fibroblasts (FF95) were provided by 
the Department of Dermatology, University of Ulm, Germany. Human epidermal melanocytes (NHEM, 
#C-12400), (M2 media, #C-24300) were purchased from Promocell GmbH, Germany. Dulbecco’s 
Modified Eagle’s Medium (DMEM #41966161), and F-10 Nutrient Mixture (Ham), #31550] were 
purchased from Gibco Life Technologies, UK, Amphotericin B # (15290018) was purchased from Gibco 
Life Technologies,Greenland, Gentamycin # (15710049) were purchased from Gibco, Life Technologies 
GmbH, China. Pen/strep, phosphate-buffered saline (PBS), and L-glutamine solutions were purchased 
from Biochrome GmbH, Germany. Thiazolyl blue tetrazolium bromide (MTT) dye, #M5655, Accutase 
solution, (#A6964), human placental type-IV collagen (#C5533), and (DMSO  (#276855) were 
purchased from Sigma-Aldrich Chemie GmbH, Germany. Diff Quick staining solution kit, (#B4132-1A) 
was purchased from Medion Diagnostic AG, Switzerland. Primary antibodies: anti-BrdU antibody, 
#555627 was purchased from BD Biosciences, USA. Secondary antibody (Alexa fluor 555 goat anti-mouse, 
(#A32727) and BrdU dye (#B23151) from Thermofisher Scientific GmbH, Germany. Bradford reagent 
#5000205 was purchased from Bio-Rad GmbH,USA. Human phospho-kinase array kit #ARY003B from 
R&D System Germany. Transwell® chambers, #3422 were procured from Corning, NY, USA, 
chemiluminescence reagent (Signal Fire, #12630S, Cell Signal), chamber slides (Millicell EZ, #C86024 
Millipore/Merck GmbH) [3,3'-((3,5-dichlorophenyl) methylene)bis(4-hydroxychroman-2-one)] (3,5-
DCPBC ) was obtained from the Molecular Bank of Dr. Panjwani Center for Molecular Medicine and Drug 
Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan. 
 
2.2. Cell culture 
Metastatic melanoma cell lines used were A375, SK-Mel-28, and WM-266-4; wherease WM115 was used 
as the non-metastatic melanoma cell line. All melanoma cell lines, and FF95 fibroblasts were grown in 
DMEM media supplemented with 200 mM L-glutamine, 50 µg/ml gentamycin/ amphotericin B solution, 100 
U/mL Pen/Strep, 20% FBS at 37 ºC, and 5% CO2 for 12 hrs prior to assay. Cells were synchronized with 
starved medium (0.2% F-10 Nut Mix Ham 1X) for further 12 hrs; thereafter, either incubated with 3,5-DCPBC 
or, in case of non-treated control group, incubated with identical volumes of DMSO in DMEM for 
the indicated concentrations and incubation times, or t hey  were grown in 2 0 % F BS  i n  DMEM. 
Human primary melanocytes were grown in M2 media. 
 
2.3. Cell cytotoxicity assay 
MTT assay was employed to evaluate cytotoxicity as previously described (Adan, Kiraz, & Baran, 2016). 
Melanoma cells, and their benign control cells were grown in 96 well plates, as described in secion 2.2. 
MTT solution was added for 4 hrs and formazan crystals were dissolved in dimethyl sulfoxide for 15 
min at room temperature. Absorbance of this solution was recorded at 550 nm to 650 nm, using a 
microplate reader (Varioskan Lux, Thermofisher Scientific). Cytotoxicity of 3,5-DCPBC was calculated 
as the relative ratio of optical densities compared to non-treated controls. 
 
2. 4. Transwell migration assay 
The Transwell® migration assay was performed as earlier described, with few modifications 
(Scharffetter-Kochanek et al., 1992). In brief, 1×105 cells in 200 μL of either starved medium or 20% FBS 
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in DMEM were loaded onto 8-micrometer pore Transwell inserts (upper chambers), and incubated for 2 
hrs at 37 °C in 5% CO2. The lower chambers were loaded either with 600 L of 20% FBS in DMEM, 
chemotactic stimuli (human placental type IV collagen) at a concentration of 100 μg/µL or dissolved in 
20% F B S  i n DMEM, and incubated for 2 hrs at 37 °C in 5% CO2. After a  4 hrs incubation period, 
cells were fixed, and stained using the Diff Quik® Stain kit. Non-migrated cells were removed from 
the upper chambers using cotton swabs. Perforated filters were removed and fixed on OT slides. An 
average number of migrated cells was counted in five high-power microscopic fields (HPF), randomly 
chosen at 20X magnification from each of the three technical and four biological replicates. Images 
of the cells migrated to the downside of the perforated membrane were collected using a Nikon TE300 
inverted epifluorescence microscope. 
 
2.5. Trypan blue cell viability assay 
Melanoma and control cells were incubated with different concentrations of 3,5-DCPBC for 4 hrs, and 
viable cells were counted using Vi-CEL XR 2.03 (Beckman Coulter, USA) automated cell counter, as 
described earlier (Kadic, Moniz, Huo, Chi, & Kariv, 2017). 
 
2.6. Bromodeoxyuridine (BrdU) incorporation assay 
Melanoma and control cells were seeded in 96-well plates, as described in section 2.2 followed by the 
treatment of 1 µM of 3,5-DCPBC/100 µL of 20% F BS in DMEM in each well for different 
incubation time. After incubation, 20 ul BrdU/100µL of 20% FBS DMEM was added to each well for 
another 2 hrs at 37 ºC, followed by fixation of cells with 1:1 acetone solution for 30 min. DNA strains 
were denatured with 2N HCl, and non-specific binding sites were blocked by 5% BSA dissolved in 
TBST. 50 µL primary anti-BrdU antibody was suspended in TBST at 1:10 dilution, and added to 
detect the incorporated BrdU dye. Melanoma cells and control cells in each well were then treated for 2 
hrs with 50 µL Alexa Fluor conjugated 555 goat anti-mouse secondary antibody, diluted in TBST at 
1:200 dilution. After washing melanoma and control cells with TBST buffer, the fluorescence of  
mixture in each well was measured in 100 µL of TBST at 548 nm excitation, and 576 nm emission. 
 
2.7. BrdU immunofluorescence staining 
Cells were grown in Millicell EZ chamber slides coated with poly-l-lysine, and were further incubated 
with 100 µM of BrdU for 2 hrs. Melanoma cells ,  and control cells were fixed with 1:1 acetone 
solution for 30 min, DNA was hydrolyzed with 2N HCl for 30 min and non-specific binding sites were 
blocked by 5% BSA dissolved in TBST. Melanoma, and control cells were incubated overnight with 500 
µL primary anti-BrdU antibody in TBST at a 1:10 dilution, washed thrice with TBST buffer, and 
thereafter, treated with 500 µL Alexa Fluor conjugated 555 goat anti-mouse secondary antibody 
suspended in TBST at a 1:200 dilution in each well for 2 hrs at room temperature. Cell nuclei were 
stained with DAPI (1µL/mL of DAPI in PBS) for 10 min, cells were fixed with formaldehyde and mounted 
with Fluoromount (Dako). Melanoma and control cells were examined under a fluorescence microscope at 
40X magnification with AxioVision A5 microscope (Zeiss Inc., Germany). BrdU positive melanoma, and 
control cells were counted manually from three independent images. The percentage of proliferating cells 
was assessed by calculating the number of BrdU-positive cells in the 3,5-DCPBC treated group, and the 
DMSO treated control group in 5 to 6 random fields. 
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2.8. The human phospho-kinase array assay, and Western blot analysis 
The phosphorylation level of kinases was determined with the Proteome Profiler Array Kit (R&D 
Systems) following the manufacturer’s instructions. Protein concentrations were determined by the 
Bradford protein assay. To block non-specific sites, each of the membranes was incubated in an array 
blocking buffer for 1 hr. 3,5-DCPBC and DMSO treated cell lysates (334 µL cell lysate/1mL of 
array buffer corresponding to 200 µg protein lysate) were applied on membranes, and incubated 
overnight. Thereafter, membranes were washed with 1X washing buffer followed by incubation with 20 
mL of the detection antibody for 2 hrs on a shaker  at room temperature. Membranes were thoroughly 
rinsed with washing buffer thrice, and further incubated with Streptavidin-HRP at room temperature for 
30 min. Membranes were washed with 1X washing buffer, for 10 min, and thereafter all membranes were 
simultaneously exposed to SignalFire plus chemiluminescent reagents for 1 min. Phospho-kinase array 
data were developed on Vilber FusionFx Chemiluminescence Imager for 1to10 min with multiple 
exposure times. 
 
2.9. Statistical analysis 
Graph Pad Prism software 5 (GraphPad Software, Inc., SanDiego, CA) was used to analyze data. 
Parametric one-way analysis of variance was used with Tukey’s posthoc analysis for comparison between 
multiple groups of 3,5-DCPBC treated, and DMSO treated groups. Student’s t-test (two-tailed) was 
employed for comparison between the two groups of counted cells taken from representative 
photomicrographs. Significance was defined as P < 0.05. P values were assigned * with P < 0.01, ** with 
P < 0.001 and *** with P < 0.0001. R studio and Cytoscape were used for data analysis and networking 
analysis respectively. 
 
3. Results 
 
3.1. 3,5-DCPBC induced cytotoxicity in metastatic, and non-metastatic melanoma 
cells  
3,5-DCPBC was synthesized using 2 molecules of 4-hydroxy coumarin and 3,5-dichlorbenzaldehyde in a 
condensation reaction, as shown in (Figure. 1 A). Cytotoxicity of 3,5-DCPBC was further assessed 
employing the MTT assay where the activity of NADPH oxidoreductase served as a measure for the extent 
of cellular toxicity. The results were compared with the optical density determined for non-treated control 
cells (20% FBS DMEM) or dimethyl sulphoxide (DMSO). We found a concentration and time-dependent 
increase in cytotoxicity in A375 melanoma cells upon treatment with 3,5-DCPBC ( Figure 1 B and C).  
3,5-DCPBC depicts cytotoxicity of more than 50% of melanoma cells upon incubation at concentrations of 
1, 10, and 100 µM for 12 hrs (Figure 1 B).  Cytotoxicity studies of 3,5-DCPBC on W M - 1 1 5 ,  a n d  
m e t a s t a t i c  SK-MEL-28 melanoma cells show similar results (Figure 1 D,  E).  To explore the 
specificity of 3,5-DCPBC for its cytotoxicity on melanoma cells, the cytotoxicity of  3,5-DCPBC was 
further assessed on human melanocytes (NHEM), and fibroblasts (FF95). It was noted, 3,5-DCPBC did not 
show any cytotoxicity on human melanocytes (NHEM), and fibroblast (FF95) at both time points (Figure 1 
G and H). 
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Figure 1 Structure and IUPAC name of 
3,5-DCPBC and its cytotoxic effects 
on different melanoma cells.                                                                                                                                                                                                              
(A) Scheme depicting the synthesis of 
3,5 DCPBC using 3,5-
dichlrobenzaldehyde with 4-hydroxy 
coumarin in the presence of 
tetraethylammonium bromide. (B-H) 
Concentration and time-dependent 
cytotoxic effect of 3,5-DCPBC on 
metastatic melanoma cells, non-
metastatic melanoma cells, primary 
melanocytes, the benign counterpart of 
melanoma cells, and fibroblasts. Equal 
concentration of DMSO dissolved in 
growth media (M2/DMEM) were used as 
DMSO controls. Data are presented as 
the relative ratio of optical densities 
compared to non-treated controls, (n = 
3) ± SEM. SEM, standard error mean. 
DMSO, Dimethylsulphoxide, M2/DMEM, 
growth media for melanocytes/ growth 
media for fibroblasts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2. 3,5 -DCPBC inhibits migration of melanoma cells 
Since cell migration is a key step in tumor metastasis (Jiang et al., 2015), inhibition of melanoma cell 
migration is of prime importance. Multi-chamber Transwell® migration assays were employed to assess 
the effect of 3,5-DCPBC on random, and directed migration of metastatic melanoma (A375, SK-
MEL-28) and non-metastatic melanoma (WM-115) cells. The suppressive effect of 3,5-DCPBC was first 
tested at three different concentrations (0.1, 1, and 10 µM) for 4 hrs on the directed migration of A375 
melanoma cells. Of note, 3,5-DCPBC effectively suppressed the directed migration of A375 melanoma 
cells at all concentrations in a dose-dependent manner ( Figure 2 A). Type-IV collagen a n d  20% FBS 
served as a strong chemoattractant (positive controls). 3,5-DCPBC impressively inhibited 20% FBS 
directed A375 melanoma cell migration (Figure 2 A, B). In fact, 3,5-DCPBC suppressed A375 melanoma 
cell migration by 93.1 % at a concentration of 1 µM compared to the control (Figure 2A, middle panel). 
Representative photomicrographs of the bottom side of the perforated membranes confirm these results 
(Figure 2 B). These data imply that 3,5-DCPBC strongly suppresses A375 melanoma cell migration. In 
order to explore whether the migration suppressing efficacy of 3,5-DCPBC is a more general property, 
other metastatic and non-metastatic melanoma cells were assessed. 
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Of note, both the directed migration of the metastatic SK-MEL-28 melanoma cells, and the non-metastatic 
WM-115 melanoma cells were similarly suppressed by 3,5-DCPBC (Figure 2C). Figure 2D depicts the 
percentage of 3,5-DCPBC suppression of directed melanoma cell migration.  This strong inhibitory effect of 
3,5-DCPBC on directed melanoma cell migration is a true anti-migratory effect, and not due to a 3,5-
DCPBC induced cytotoxicity (Figure 2E). A375 melanoma cells were found to be viable in the range of 90.9 
to 93.3% in 3,5-DCPBC treated group as compared to DMSO control groups (97.3%, and 95.03%, 
respectively) during the studied migration period of 4 hrs.  
 
3.3. 3,5 -DCPBC diminishes metastatic melanoma cell proliferation 
The effect of 3,5-DCPBC was further explored on the proliferation of metastatic A375 melanoma 
cells as a prime event in melanoma progression. For this purpose, BrdU incorporation was studied as 
previously described (Bundscherer et al., 2008). The DNA thymidine analog 5-bromo-2’-deoxyuridine 
(BrdU) was allowed to incorporate into rapidly growing metastatic melanoma cells during the S 
phase of the cell cycle in the presence, and absence of 3,5-DCPBC and thereafter was detected by an 
antibody directed against BrdU, employing a fluorometer at 548 and 576 nm excitation and emission,  
Figure 2  3,5-DCPBC profoundly inhibits 
directed melanoma cell migration.   (A) 
Migration assays were performed as detailed in 
Materials and Methods.  The migration of A375 
melanoma cells in the presence of 3,5-DCPBC 
at the indicated concentrations was tested 
employing human placental type IV collagen at a 
concentration of 100 μg/µL dissolved in 600 µL 
20% FBS, which serves as a chemoattractant. 
DMEM, Dulbecco’s Modified Eagle’s Medium; 
DMSO; Dimethylsulphoxide; FBS, fetal bovine 
serum.  (I) Positive control (Collagen type-IV), 
(II) FBS control (0.2% starved FBS/20% FBS 
DMEM), (III) DMSO Control (DMSO+ 0.2% 
starved FBS/20% FBS DMEM), (IV) Random 
Control (20% FBS DMEM/DMEM), (V) (DCPBC) 
at the indicated concentrations in the upper and 
lower chambers + (0.2% FBS starved/20% FBS 
DMEM), (VI) Melanocytes were tested for their 
migratory response towards  20% FBS in DMEM 
(chemoattractant)  (B) Representative 
photomicrographs of the bottom side of the 
perforated membranes from the experiments 
described in Fig. 2 (A); bars, 10 µm. (C) 
Comparison of the inhibitory activity of 1 µM 3,5-
DCPBC on the directed migration of different 
primary and metastatic melanoma cell lines, and 
melanocytes. The differently tested groups (I-VI) 
are as described in Fig. 2(A).  (D) Percentage of 
inhibition of the directed migration of metastatic, 
and non-metastatic melanoma cells by 1 µM 3,5-
DCPBC.  (E) Effect of 1 µM 3,5-DCPBC on the 
viability of metastatic melanoma A375 cells. 
Data are shown as mean ± S.D; n = 3 replicates; 
graphs represent one of three independent 
experiments; ***p < 0.0005 calculated by one-
way ANOVA between 3,5-DCPBC treated 
melanoma cells and controls. Bars represent the 
means of triplicate determinations, and error 
bars indicate the standard deviations 
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respectively. 3,5-DCPBC efficiently suppressed melanoma cell proliferation at 48 hrs of treatment 
(Figure 3A). This anti-proliferative 3,5-DCPBC effect corresponds to an average of the relative 
fluorescence of 1, compared to 4.9 of the DMSO control at the same time point (Figure 3A). In a 
complementary approach, BrdU positive cells from immunofluorescence photomicrographs were 
quantitated, and the percentage of BrdU positive cells were significantly reduced (Figure 3B). These data 
indicate the anti-proliferative effect of compound 3,5-DCPBC on A375 metastatic melanoma cells. 
 
3.4. 3,5 -DCPBC does not alter the intracellular redox state 
Metastatic melanoma progression is known to driven by reactive oxygen species (ROS) be in part, and in 
particular, the migration and proliferation of metastatic melanoma cells are enhanced by an intracellular 
increase in superoxide (O2
.-) and hydrogen peroxide (H2O2) levels (Bisevac et al., 2018; Dan Dunn, 
Alvarez, Zhang, & Soldati, 2015; Denat, Kadekaro, Marrot, Leachman, & Abdel-Malek, 2014).  
Figure 3  3,5-DCPBC inhibits melanoma cell 
proliferation and lacks antioxidant properties.  
(A) A375 metastatic melanoma cells were cultured in the 
presence of 1 µM 3,5-DCPBC or 1 µM Dimethyl sulfoxide 
(DMSO). A pulse of BrdU was provided for 2 hrs. 
Proliferation of BrdU incorporating A375 melanoma cells 
was assessed at the indicated time points by a fluorescence 
spectrometer at excitation 548 nm-emission 576 nm. The 
red graph corresponds to 3,5-DCPBC treated, and the black 
graph to non-treated A375 melanoma cells. Data are 
presented as mean ± standard deviation (SD). *P < 0.05, 
between treated and non-treated cells at 24 h. ***P < 
0.0001 between treated and non-treated cells at 48 h. 
Independent experiments were repeated three times. 
DMSO, vehicle control; DMSO, dimethyl sulfoxide. Asterisks 
indicate statistical difference determined by unpaired 
student’s t-test. (B) Fluorescence images of BrdU 
incorporation indicative of A375 melanoma cell proliferation 
after treatment with 1µM 3,5-DCPBC (right panel) or, as 
control with 1µM DMSO (left panel) for 48 hrs.  (C) 
Quantification of BrdU positive A375 melanoma cells with 
original data from Fig. 3 (B). Data are presented as mean± 
SEM. n> = 3, ***p< 0.0003. Asterisks indicate the statistical 
difference determined by unpaired student’s t-test. (D) Dose 
response relationship between 3,5-DCPBC at the indicated 
concentrations, and changes in cytosolic ROS levels. N-
acetylcysteine (NAC) and rotenone (Rot) were used as a 
ROS quenching and ROS enhancing agents (positive and 
negative control) respectively. DMSO served as vehicle 
control. Histograms showing the mean ± SD value of DHE 
fluorescence intensities indicative of ROS levels. Statistical 
analysis was carried out by one-way ANOVA. (E) The 
MitoSOX assay was employed to assess dose-dependent 
changes in the mitochondrial ROS levels, in particular 
mitochondrial O2-. upon treatment of A375 melanoma cells 
with 3,5-DCPBC at the indicated concentrations. Values are 
shown as mean ± SD (n = 3) of fluorescence intensities for 
ROS. Statistical analysis was carried out by one-way 
ANOVA. (F) Time kinetic of on cytosolic ROS levels upon 
treatment of A375 melanoma cells with 1 µM 3,5-DCPBC. 
The fluorescence intensity and statistical analysis was 
assessed as in Figure 3 (D). (G) Time kinetic of 
mitochondrial ROS levels upon treatment of A375 
melanoma cells with 1 µM 3,5-DCPBC. The fluorescence 
intensity and statistical analysis was assessed as described 
in Figiure 3 (E) 
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To investigate whether 3,5-DCPBC exerts its anti-proliferative and anti-migratory effect by potential 
antioxidant properties, the effect of 3,5-DCPBC on mitochondrial and cytosolic superoxide (O2
.-), and 
H2O2 levels was studied employing the DHE and MitoSOX assays (Dikalov & Harrison, 2014). DHE is 
a fluorescent probe for the detection of cytoplasmic O2
.-
 and H2O2, MitoSOX
TM Red identifies 
mitochondrial O2
.-
. Briefly, A375 melanoma cells were incubated with MitoSOX
TM Red or DHE dye 
in the presence, and absence of 3,5-DCPBC, and fluorescence was measured by a fluorescence 
spectrophotometer. High fluorescence indicates low free radical scavenging potential of tested 3,5-
DCPBC. 3,5-DCPBC at all tested concentrations did not exhibit any significant antioxidant effect on 
cytosolic or mitochondrial O2
.- and H2O2 (Figure 3 D, E) in A375 melanoma cells. By contrast with 3,5-
DCPBC, both rotenone, a complex I inhibiting agent which increases mitochondrial O2
.-
 as well as N-acetyl 
cysteine (NAC) serving as a substrate for the H2O2 removing classical glutathione peroxidase, depict 
strong effects on ROS levels (Figure 3D, E, F, G). We found that 3,5-DCPBC did not modulate intracellular 
redox state by scavenging mitochondrial/cytosolic O2
.- or H2O2 concentrations. These data imply that the 
Figure 4  3,5-DCPBC impacts on phosphorylation of 
multiple kinases. Cell lysates from A375 melanoma 
cells treated with either 1 µM DMSO (control) (A,C) or 
with 1 µM 3,5-DCPBC for 4 hrs (B,D) were incubated 
with PVDF-membranes with anchored antibodies for 
phosphor-Y1086-EGFR (spot 1), phospho-Y-751-
PDGF-β (spot 2), phosphor-S-2448-mTOR (spot 3), 
phosphor-T246-PRAS40 (spot 4), phospho-
T202/Y204/T185/Y187-ERK1/2 (spot 5), phosphor-Y-
419-Src (spot 6), phospho-Y-397-Lyn (spot 7), 
phosphor-Y-394-Lck (spot 8), phosphor-Y-420-Fyn 
(spot 9), phosphor-Y426-Yes (spot 10), phosphor-Y-
412-Fgr (spot 11), phosphor-Y-411-Hck (spot 12), 
phosphor-Y-397-FAK(spot 13), phosphor-Y689-STAT2 
(spot 14), phosphor-Y-694- STAT5α (spot 15), 
phosphor-Y641-STAT6 (spot 16), phosphor-Y-694/699-
STAT5α/β (spot 17), phosphor-S376/S360-MSK1/2 
(spot 18), phosphor-S133-CREB (spot 19), phosphor-
T68-Chk-2 (spot 20), phosphor-S-392-p53 (spot 21), 
phosphor-S-46-p53 (spot 22), phosphor-S78/S82-
HSP27(spot 23), phosphor-S21/S9-GSKα/β (spot 24), 
and phosphor-β-catenin (spot 25). Membranes were 
developed with appropriate secondary antibodies, and 
the spots were detected using a chemiluminescence 
based assay, as detailed in Material and Methods. (E) 
Densitometric analysis of the phosphorylation state of 
multiple kinases from Fig.4 (A-D) employing gel quant 
software. Results are expressed as “Arbitrary Density 
units”, and presented as mean ± S.D. for 3 independent 
experiments. Data are analyzed by one-way ANOVA 
and the statistical difference are shown as *p values. 
(F) Differential phospho-regulation is plotted using MA 
plot. X-axis represent the mean expression and y-axis 
represents log2 fold change, the genes that are more 
than two-fold differentially regulated are shown in blue 
whereas the non-significant one is shown in grey. (G) 
Phosphorylation motifs were analyzed from the 16 
differentially downregulated phosphokinase motifs from 
(F). (H)  represents the pathway analysis carried out 
depicting those genes from the 16 regulated phospho-
sites. X-axis represents the gene ratio, whereas the 
associated pathways are represented in y-axis. The 
color of the circles represents the level of significance 
as p values adjusted. 
 
10 
 
observed suppression of proliferation, and migration on melanoma cells is not due to antioxidant 
properties of 3,5-DCPBC.  
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3.5 Molecular mechanism of action of 3,5-DCPBC 
To gain insight into the mechanism of how 3,5-DCPBC inhibits melanoma cell survival, growth, 
proliferation, and migration, a  phospho-proteome profiling array was employed. A375 melanoma 
cells were treated with 3,5-DCPBC at a concentration of 1 µM for 4, and 18 hrs. For each time point, a 
total of 43 kinase phosphorylation sites and 2 related proteins (HSP, and tumor suppressor proteins) were 
analyzed. A significant effect of compound 3,5-DCPBC was observed on 31 phosphorylation sites of 25 
different kinases at 4 hrs, and 11 phosphorylation sites of 6 different kinases at 18 hrs. Altogether, 36 
phosphorylation sites of 27 different kinases were found to be potential targets of 3,5-DCPBC as 
opposed to the DMSO control, (Figure 4 A, C, and B, D). A list of non-affected kinases is attached  as 
(Supplementary Tables 1 and 2). Densitometric analysis of significant phosphorylation sites of  the 25 
kinases along with their associated P values is shown in Figure 4 E.  Sixteen different kinases were more 
than 2-fold down-regulated upon treatment with 3,5-DCPBC as compared to DMSO (Figure 4 F). The 
MA plot depicts Log2 fold changes on y-axis, and Log2 mean expression on x-axis (Figure 4 F). Eleven 
kinases did not show any significant changes. Among the 16 differentially down-regulated 
phosphokinases, predominantly members of the family of the tyrosine kinase family were suppressed,  
Figure 5 3,5-DCPBC reduces phosphorylation 
(activation) of multiple kinases in melanoma cells. 
(A, B, C, D) A375 metastatic melanoma cells were 
treated with 1 µM 3,5-DCPBC for 18 hrs.  Cell lysates 
from the DMSO treated (control) (A), and 3,5-DCPBC 
treated (B) A375 melanoma cells were incubated with 
PVDF-membranes with anchored antibodies for 
phosphor-T183,221/Y185,223-JUNK1/2/3 (spot 1), 
phosphor-T183-AMPKα1(spot 2), phosphor-
S376/S360-MSK1/2 (spot 3), phosphor-S133–CREB 
(spot 4), phosphor-S21/S9-GSK-3αβ/ (spot 5), and 
phosphor-Y420-Yes (spot 6). Membranes were 
developed with appropriate secondary antibodies, and 
spots were detected using a chemiluminescence based 
assay, as described in Material and Methods. (E) The 
phosphorylation (activation) state of kinases was 
determined by densitometry analysis from data of Fig. 
5 (A, B, C, D). Results are expressed as “Arbitrary 
Density units”, and presented mean ± S.D. for 3 
independent experiments. Data is analyzed by one-
way ANOVA and the statistical difference are shown as 
*p values. (F) The association between x-axis 4 hrs 
downregulation vs y-axis 18 hrs down-regulation (blue 
colored box) includes AKT1, STAT3, EGFR. (G) 
Correlation plot between highly correlated genes at 4 
and 18 hrs (F) is depicted as scatterplot, indicting 
differential phosphorylation between 375 melanoma 
cells treated with 3,5-DCPBC for 4 vs 18 hrs. The x-
axis represents fold change of 4hrs DCPBC/DMSO 
treatment, and the y-axis represents fold change of 
18hrs DCPBC/DMSO treatment. (H) Pathway analysis 
of significantly down-regulated genes in 375 melanoma 
cells treated with 3,5-DCPBC for 4 vs 18 hrs. 
Differentially regulated genes with more than 2-fold 
change was included in this pathway analysis. The 
pathways are represented in the y-axis and the gene 
ratio in the x-axis. Color represents the level of 
significance, and p value adjusted. Data is analyzed by 
one-way ANOVA and the statistical difference are 
shown as *p<0.05, **p<0.05 and ***p<0.001 when 
compared between treated and control cells 
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The tyrosine kinase phospho-motif (blue filled circles) is the most affected phospho-motif in A375 
melanoma cells treated with 3,5-DCPBC as compared to threonine (green filled circles) or serine (pink 
filled circles). Phospho-motif mapping thus allowed us to uncover major kinases and signaling pathways 
targeting key genes for melanoma progression. Pathway analysis was further employed for the most 
suppressed kinases with downregulation of phospho-motifs to explore which signaling pathways are most 
prominently affected (Figure 4 H). The x-axis represents the gene ratio which is presented as % of total 
differential gene expression (DGE) in all GO clusters, and the y-axis represents the associated pathway. 
The color refers to the P-value, and the count as the number of occurrences of this gene per GO cluster. 
Pathway analysis with the differentially down-regulated phosphor-motifs depict receptor tyrosine kinases, 
inflammatory interleukins and ERK1/2, AKT, and mTOR as the major signaling cascades that are affected 
after treatment of melanoma cells with 3,5-DCPBC. Briefly, phosphor tyrosine modulation at a specific 
residue of Epidermal Growth Factor Receptor (EGFRY1086) and Fc gamma ReceptorsY412, and their 
downstream target JAK/STAT pathway were the most suppressed target including STAT2Y689, 
STAT5αY697, STAT5α/βY694/Y699, and STAT6Y641. Among the other 3,5-DCPBC suppressed 
pathways highly important for melanoma progression, are mTORS2448, ERK1/2 Y
204
/ Y
187
, SRCY419, and β-
Figure 6 3,5-DCPBC impacts on important 
regulatory hubs in melanoma progression.  
(A)  Gene enrichment and networking depicts 
relevant nodes and edges, among them 9 
genes, namely, EGFR, STAT3, STAT5A, 
STAT5B, AKT1, LYN, LCK, P53, and P38a. 
Nodes and the edges are subdivided into 
signaling pathway (represented in blue color), 
some of them are associated with a variety of 
cancers including melanoma (the latter 
highlighted in red). All uncovered 9 nodes show 
a strong interdependence with the key signaling 
pathways [EGFR/STAT axis] / [EGFR/SRC axis]/ 
[EGFR/RAS/MAPK axis]/ [EGFR/PI3K/AKT 
axis]. The nodes were unweighted and 
connected using Waserman and Faust 
algorithm. Network mapping shows that these 
genes depict a strong cross talk, and are 
associated with malignancies including 
malignant melanoma. (B) Summary scheme 
depicting 3,5-DCPBC targeting EGFR and SRC 
kinases, AKT/mTOR and RAS/RAF/MAP 
kinases. Taken together, 3,5-DCPBC shows 
excellent tyrosine kinase inhibiting properties. 
Most excitingly, it is endowed with the potential 
to target multiple kinases to prevent cellular 
migration (via SRC), ER stress survival (via 
p38α), proliferation and protein synthesis (via 
AKT/mTOR). Red circles with p indicate the 
genes in the signaling cascade, which could be 
post translationally regulated with 
phosphorylation at kinase sites as well as which 
were found to be significantly downregulated in 
melanoma cell after 3,5-DCPBC treatment in 
comparison with the controls 
 phosphorylation of serine or 
threonine kinases was less frequently 
affected (Figure 4 G). The y-axis 
represents the fold change, and the 
x-axis represents the position of the 
phospho-sites in the gene amino acid 
sequence (Figure 4 G). 
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CateninY654.  In order to understand whether inhibition of phosphosites following treatment of 375 melanoma 
cells with 3,5-DCPBC will persist for 18 hrs, phosphokinase array analysis was performed  (Figure 5A, B, 
C, D): Densitometric analysis from A-D depicts the downregulation of phosphor-sites is not maintained in 
all identified phosphokinases (Figure 5 E).  Of note, as shown in the blue box of the correlation plot (Fig. 
5F), EFGFR, AKT1, 2, and 3 and STAT3 at 18 hrs of 3,5 DCPBC are still profoundly suppressed.  These 
phosposites are mainly from tyrosine kinases (Figure 5G), and they impact on the genes involved in tyrosine 
kinase signaling (Figure 5H). 
  
4. Discussion 
 
The major unprecedented finding of this study is that the newly synthesized bis-coumarin derivative 
referred to as 3,5-DCPBC has profound inhibitory properties on key steps of malignant melanoma 
progression (Wirbel, Cutillas, & Saez-Rodriguez, 2018). Accordingly, proliferation, migration, and 
survival of melanoma cells - by contrast to melanocytes, their benign counterpart, or fibroblasts - are 
impressively downregulated in vitro in the presence of moderate concentrations of 3,5- DCPBC. The 
strong effect on key features of melanoma progression is not due to any antioxidant property of 3,5-
DCPBC, though ROS have been reported to be associated with melanoma pathophysiology, but rather a 
consequence of its outstanding suppressive potential of the major different tyrosine phosphokinases 
involved in melanoma progression (see summary graph Figure. 6). In fact, phosphokinases modulate 
several cellular functions (Nishi, Shaytan, & Panchenko, 2014), and activation of multiple phosphokinases 
has been implicated in melanoma, and many cancers including autophosphorylation of Epidermal Growth 
Factor Receptor (EGFR) (Boone et al., 2011; Davies, 2012) Of note, compound 3,5-DCPBC significantly 
diminished the phosphorylation of the Y1086 of EGFR  and Y751 of  PDGFR at 4 hrs (Figure 4 E, F, 
Figure 5E and Supplementary Table-1). As phosphorylation of these residues of EGFR and PDGFR 
regulates various signal transduction pathways (mTOR, SFK, JAK-STAT, and MAPK) involved in cell 
proliferation, cell migration as well as cell survival,  are found to be hyperphosphorylated in various 
cancers including melanomas (Dratkiewicz, Simiczyjew, Pietraszek-Gremplewicz, Mazurkiewicz, & 
Nowak, 2019; Girotti et al., 2013; Nazarian et al., 2010; Welsh, Rizos, Scolyer, & Long, 2016), we further 
studied the downstream pathways, and their associated genes that are regulated through EGFRY1086 
phosphorylation (Figure 4 H). Hyperphosphorylation of mTOR at its threonine Thr2446, serine residues 
(Ser2448, and Ser2481) via EGFR- ERK–S6K1 and PI3K/AKT axis (Copp, Manning, & Hunter, 
2009), linked to growth in various types of cancers and melanoma (Holroyd & Michie, 2018), was 
markedly downregulated upon 3,5-DCPBC treatment, as confirmed by downregulation of 16 genes within 
the mTOR pathway (Figure 4 F). Suppression of phosphorylation (activation) of the mTOR pathway 
(mTOR, PRAS40, and ERK1/2/3) was observed only at 4 hrs after 3,5-DCPBC treatment. EGFR 
phosphorylation can activate the Src family of kinases (SFKs) (Halaban et al., 2019), they consequently 
play key roles in cell differentiation, motility, proliferation, and survival (Irwin, Bohin, & Boerner, 
2011), Tyrosine phosphorylation of members of SFKs including SRCY419, LYNY397, LCKY394, 
FYNY420, YesY426, FGRY
412
, HCKY41, and FAKY319 were all profoundly down-regulated in A375 
malignant melanoma cells treated with 3,5-DCPBC. The finding that the newly synthesized compound 3,5-
DCPBC has the potential to simultaneously suppress many phospho-tyrosine kinases, among them EGFR 
and SRC, is of major clinical relevance. In fact, the simultaneous inhibition of tyrosine phosphorylation of 
EGFR and SRC kinases has recently been reported to overcome the frequently developing BRAF resistance 
in melanoma (Girotti et al., 2013). Of major importance among other contributing downstream signaling 
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pathways of EGFR is the JAK/STAT axis (Pansky et al., 2000), whose tyrosine phosphorylation at 
STAT2Y689, STAT5αY697, STAT5α/βY694/Y699, and STAT6Y641 is significantly reduced in A375 
malignant melanoma cells when treated with 3,5-DCPBC. In addition, phosphorylation on Y705/727 and 
Y694/699 of STAT3, and STAT5α/β most likely in cooperation with MSK (nuclear serine/threonine protein 
kinases that are activated by members of MAPK families), enforce phosphorylation of ERK1/2 
(extracellular signal-regulated kinase) or of p38 in a growth factor receptor-independent signaling 
pathways (Koul, Pal, & Koul, 2013). These pathways are essential for melanoma progression, and their 
inhibition by 3,5-DCPBC and may suppress melanoma cell survival and proliferation (Estrada, Dong, & 
Ossowski, 2009; Mirmohammadsadegh et al., 2007; Zhuang et al., 2005) 
Conclusion 
 
In conclusion, with urgent need for new therapeutics to target multiple tyrosine kinases as a newly 
emerging concept for advanced melanoma, 3,5-DCPBC might hold promise for an efficient alternative 
approach to currently established therapies (Girotti et al., 2013; Hartmann et al., 2015; Kourie & 
Klastersky, 2016; Vojnic et al., 2019). In fact, we here discovered that 3,5-DCPBC is highly suppressive on 
many steps and pathways of melanoma cell progression at very low concentrations, and is non-toxic 
for non-tumorous melanocytes, and fibroblasts. The efficient combined targeting of EGFR, SRC, and 
MAPK by 3,5-DCPBC in melanoma cells may assist clinicians in long term prevention of tumor cell 
proliferation, and even overcoming drug resistance. Further preclinical data are now required, and, 
thereafter clinical trials for this compound are the next highly interesting steps. 
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